Harrow, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. on May 30, 2019. The filing addresses a specific legal event under Item 8.01 (Other Events) involving a dispute with Novel Drug Solutions, LLC and Eye Care Northwest, PA (collectively "NDS").
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal contingency and does not contain financial performance data.
Material Changes and Legal Contingency
- Event: On May 30, 2019, NDS issued a press release claiming to have delivered a termination notice to Harrow regarding an asset purchase agreement dated August 8, 2013.
- Legal Status: The parties are currently involved in a lawsuit related to this agreement.
- Company Position: Harrow believes the claims filed by NDS are meritless.
Management Commentary and Outlook
Management states that the receipt of the purported termination notice and the ongoing lawsuit with NDS are not expected to affect the Company's ImprimisRx business. Specifically, operations, revenues, and the ongoing service of customers are anticipated to remain unaffected.
Key Facts for Investor Verification
- Verify the current status of the lawsuit between Harrow and NDS regarding the 2013 asset purchase agreement.
- Confirm that the ImprimisRx business operations remain stable despite the legal dispute.
- Review subsequent filings for any updates on the termination notice or litigation outcomes.